SIRT1 and fatty liver disease: In mammals, studies showed that low levels of serum SIRT1 were observed in obese patients with liver steatosis, and liver-specific SIRT1-knockout mice showed hepatic lipid accumulation, suggesting that SIRT1 was a negative modulator of the SREBP-1 lipogenic pathway (28–31).